Moderna, Inc. (NASDAQ: MRNA) has released its financial results for the first quarter of 2024, along with key updates on its business operations. Stéphane Bancel, the Chief Executive Officer of Moderna, emphasized the company’s strategic approach amidst the impending launches…
Encouraging findings emerge from an interim analysis of the ECHO Phase III trial, indicating that AstraZeneca’s Calquence (acalabrutinib), when paired with standard-of-care chemoimmunotherapy—bendamustine and rituximab—achieved a significant improvement in progression-free survival (PFS) compared to standard treatment in previously untreated adults…
Amgen (NASDAQ:AMGN) today announced that it will report its first quarter 2024 financial results on Thursday, May 2, 2024, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 4:30 p.m. ET. Participating…
AstraZeneca will showcase new clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American Thoracic Society (ATS) International Conference, in San Diego, CA from 17 to 22 May 2024. The company will present…
AstraZeneca’s Truqap (capivasertib) combined with Faslodex (fulvestrant) has received a positive recommendation for approval in the European Union (EU) for treating adult patients with locally advanced or metastatic breast cancer that is estrogen receptor (ER)-positive and HER2-negative. This recommendation comes…
AbbVie Initiates Construction of State-of-the-Art Research Hub, “LUnA,” in Germany with €150 Million Investment AbbVie has commenced the construction of its new central research building, dubbed “LUnA” (LUdwighafens neue Arbeitswelt), solidifying its commitment with approximately €150 million investment in its…
Merck (NYSE: MRK), also known as MSD outside of the United States and Canada, has revealed findings from its Phase 3 trial, STRIDE-10, assessing V116, the company’s advanced 21-valent pneumococcal conjugate vaccine designed for adults. The announcement took place at…
Eli Lilly and Company (NYSE: LLY) unveiled its financial performance for the first quarter of 2024 today. David A. Ricks, Lilly’s chair and CEO, commented on the company’s robust year-over-year revenue growth, attributing it to strong sales of Mounjaro and…
Eli Lilly and Company (NYSE: LLY) has received notification of an unsolicited “mini-tender” offer from Tutanota LLC (“Tutanota”), proposing to acquire up to 62,500 shares of Lilly common stock, which represents significantly less than one percent of Lilly’s outstanding common…
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a prominent global oncology firm, has unveiled its 2023 Responsible Business & Sustainability Report, spotlighting the company’s strategic direction, progress towards existing objectives, and its vision for achieving ambitious new targets. This…
Moderna, Inc. (NASDAQ: MRNA) has unveiled plans to share insights from its extensive respiratory portfolio, encompassing vaccines and vaccine candidates targeting COVID-19 (mRNA-1273, mRNA-1283), influenza (mRNA-1010, mRNA-1011/1012), and respiratory syncytial virus (RSV) (mRNA-1345), along with data pertaining to its latent…
Biogen Inc. (Nasdaq: BIIB) has announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a favorable opinion for TOFIDENCE™ (tocilizumab), a biosimilar monoclonal antibody referencing ROACTEMRA®1. The intravenous formulation…